Marinomed Biotech Announces Capital increase with subscription rights
Marinomed Biotech AG ("Company") has decided, due to a short-term need for capital, to increase its share capital by up to EUR 459,985 through the issuance of up to 459,985 new shares (“New Shares”) and to carry out a capital increase. The goal of the transaction is to generate gross proceeds of at least EUR 2 million for the company.
The New Shares will be offered as part of a prospectus-exempt offering pursuant to Article 1(4)(db) of Regulation (EU) 2017/1129 (“Prospectus Regulation”), as amended, based on a document in accordance with Annex IX of the Prospectus Regulation, which will be published prior to the commencement of the public offering. The subscription offer is scheduled to begin on March 26, 2026, and will have a statutory minimum duration of two weeks. Any New Shares not subscribed for will be offered following the subscription offer as part of a prospectus-exempt private placement (“rump placement”) to eligible institutional investors and selected non-institutional investors within the European Economic Area at the subscription price. A binding commitment has already been received from an institutional investor who, as of today, does not yet hold any shares in the Company, to subscribe for and acquire New Shares in the aggregate amount of EUR 1 million at the subscription price as part of the short placement. In the past, due to the Company’s restructuring proceedings, it was necessary and appropriate to exclude shareholders’ subscription rights in connection with recent cash capital increases in order to ensure and carry out a swift capital measure. As part of the current rights offering, existing shareholders have the opportunity to participate in the capital increase on a 4:1 basis (four existing shares entitle the holder to subscribe for one new share) and to maintain their ownership stake in the company’s share capital. The subscription price per new share has been set at EUR 14.
Because the Company has not yet received sufficient payments from the transfer of the Carragelose business to Unither Pharmaceuticals, the Company has a short-term capital requirement to cover its anticipated liquidity needs of approximately EUR 2 million until mid of the fiscal year 2026. The net proceeds from the capital increase are therefore to be used to fulfill the restructuring plan and close the financing gap.
“Marinomed’s business plan projects profits for 2026 and subsequent years, which are expected to be generated through the successful marketing of our flagship products, Budesolv and Tacrosolv. We expect to receive payments in the range of several million euros from partnerships and the licensing of our flagship products through deals currently in the pipeline. Because there have been delays in the earn-out payments from the sale of the Carragelose business, this capital measure will close this liquidity gap, and shareholders have the opportunity to participate in the measure by subscribing to new shares,” commented Andreas Grassauer, CEO of Marinomed.
Marinomed is also releasing preliminary and unaudited figures for the 2025 fiscal year today.
Preliminary Financial Figures for 2025
According to these figures, revenue rose to €7.7 million in 2025 (2024: €4.7 million). This includes an advance payment of €5 million from the sale of the Carragelose business. Other operating income of €19.5 million includes a restructuring gain of €18.9 million as well as the Austrian research grant. Preliminary personnel expenses amounted to €4.0 million in 2025, compared to €4.8 million in 2024. This reflects the initial optimization measures implemented during the year. The Liquid assets amounted to approximately €1 million as of December 31, 2025.
Contact
Marinomed Biotech AG
PR: Luca Horinek
IR.: Tobias Meister
T: +43 2262 90300 158
E-Mail: pr@marinomed.com
E-Mail: ir@marinomed.com